TGFB1 and neoplasm: Bone resorption during osseous disease results in the release of sequestered transforming growth factor beta (TGFB), which together with interleukin 6 (IL-6) produced by bone marrow stromal cells, can act on resident T cells to preclude tumour killing (Jiao et al. 2019).